EarningsQ2 2026 Earnings Report
DE:2B30 Q2 2026 EPS Results
Actual EPS-€0.16
Consensus EPS€0.01
Beat/MissMissed by -€0.17
One Year Ago EPS>-€0.01
DE:2B30 Q2 2026 Revenue Results
Actual Revenue€82.03M
Expected Revenue€80.27M
Beat/MissBeat by +€1.76M
YoY Revenue Growth+28.74%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeBefore Open
Conference CallThursday, August 6, 2026
DE:2B30 Upcoming Earnings
Xeris Pharmaceuticals's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:2B30 Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum (notably Recorlev’s 81% YoY growth), improved profitability (86% gross margin, adjusted EBITDA +50% YoY), strategic wins (Keveyis patent protection, retirement of convertible notes) and material pipeline progress for XP-8121 (multiple patents, Phase III planned by year-end). Lowlights were largely manageable: a one-time non-cash GAAP charge of ~$31M, higher near-term SG&A and R&D investments to fund growth and XP-8121, earlier-year softness in Gvoke that has since rebounded, and some remaining timing/enrollment uncertainty around Phase III. Overall, positive commercial execution and balance sheet actions outweigh the near-term charges and increased investment cadence.Company Guidance
Record Quarterly Revenue and Strong YoY Growth
Total revenue of $92.1M and net product revenue of $91M in Q2 2026, representing year-over-year growth of ~29% (total revenue) and ~34% (net product revenue). First half revenue growth of 33% and company raised the bottom end of full-year 2026 guidance to $385M–$390M (tightened $5M range).
Recorlev Outstanding Performance
Recorlev net revenue of ~$56.8M in Q2, up 81% year-over-year (increase of >$25M). Company reported record referrals, new patient starts, patients on therapy, new prescribers and total prescribers; expansion of commercial team expected to drive further acceleration in H2.
Gvoke Sequential Recovery
Gvoke net revenue of ~$22.5M in Q2, rebounding after a slow start; management reported sequential prescription growth (management cited ~10% q/q prescription growth; CFO cited ~8% sequential revenue increase). Company expects a seasonal back-to-school lift in Q3 and reaffirmed long-term opportunity (~15M people with diabetes who should have product vs ~1M currently reached).
Keveyis Durability and Patent Protection
Keveyis net revenue of ~$11.7M in Q2 demonstrating durable performance in an ultra-rare market. Received notice of allowance for a new U.S. patent (filed June 11) that, when issued, will provide protection for Keveyis through at least 2039; company plans incremental investment in Keveyis and the PPP community.
Convertible Notes Retirement and Stronger Balance Sheet
Completed full retirement of 2028 convertible notes in July (settled with cash and equity). Eliminated ~$34M of debt and expects approximately $3M in annual interest savings; management emphasized a cleaner capital structure enabling further investments.
Improved Profitability Metrics
Gross margin approximately 86% in Q2, an improvement of ~400 basis points year-over-year driven by favorable product mix. Adjusted EBITDA of $19.3M in Q2, up $6.7M versus prior year (>50% year-over-year increase) despite incremental commercial and R&D investments.
XP-8121 Clinical and IP Progress
XP-8121: finalized clinical site selections and preparing for an expected Phase III start by year-end; received a second U.S. patent on July 28 and a notice of allowance for an additional U.S. patent (third) the prior week. Company scheduled an XP-8121 program overview webinar for September 9 and continues to target a 2030 launch trajectory.
DE:2B30 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed